Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Questions Evidence For Janssen’s Xarelto In Acute Coronary Syndrome

This article was originally published in The Pink Sheet Daily

Executive Summary

Although FDA suggested the sponsor consider a limited duration of use for rivaroxaban in the ACS setting, advisory committee briefing documents reflect doubts about the strength of analyses supporting such a claim.

You may also be interested in...



J&J To Persevere In ACS After Another “Complete Response” For Xarelto

J&J says it remains confident about getting expanded approval for Xarelto after receiving a “complete response” letter from FDA for reducing risk of stent thrombosis in patients with acute coronary syndrome.

Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim

The agency’s decision not to approve the Factor Xa inhibitor for treating acute coronary syndrome patients follows a negative recommendation by an FDA advisory committee, which was concerned about missing data in the pivotal ATLAS trial. FDA may be seeking more clarity on the issue of missing vital status follow-up for patients who withdrew consent in that study.

Xarelto Review Sparks Debate Over Feasibility Of A Three-Drug ACS Regimen

While the focus of the Cardiovascular and Renal Drugs Advisory Committee’s meeting was on rivaroxaban’s use in treating acute coronary syndromes, some panelists questioned the wisdom of adding an antithrombin to current dual-antiplatelet therapy standard of care. The lack of data on rivaroxaban’s use with the two newest antiplatelet agents, prasugrel and ticagrelor, also could prove problematic from a labeling perspective due to theoretical concerns about increased bleeding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076373

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel